RecruitingPhase 3Drug trialA Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderX-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)